HUTCHMED (China) Ltd (HCM) Full Year 2025 Earnings Call Highlights: Strong Global Expansion and ... [Yahoo! Finance]
HUTCHMED (China) Limited - American Depositary Shares (HCM)
NASDAQ:AMEX Investor Relations:
chi-med.com/investors/information-for-shareholders
Company Research
Source: Yahoo! Finance
This article first appeared on GuruFocus Ex-China FRUZAQLA Sales Growth: 26% growth, resulting in $366 million in in-market sales. China Sales Growth: 21% in-market sales growth in the second half of the year. Cash Position: Approximately $1.4 billion. Total Oncology Revenue: $286 million, including $71 million from R&D-related upfront and milestone revenues. Net Income: $457 million, primarily due to a $416 million gain from SHPL divestment. R&D Expenses: $148 million, lower than 2024. Oncology Revenue Guidance for 2026: $330 million to $450 million. FRUZAQLA Global Expansion: Rolled out to over 38 countries. ELUNATE China Sales Growth: 33% growth in the second half of the year. ORPATHYS and SULANDA Sales: 11% of total 2025 in-market sales, facing competition. Hematology Portfolio Launch: First-in-class treatment for EZH2 mutation and follicular lymphoma approved in China. Warning! GuruFocus has detected 7 Warning Signs with HCM. Is HCM fairly valued? Test
Show less
Read more
Impact Snapshot
Event Time:
HCM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HCM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HCM alerts
High impacting HUTCHMED (China) Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
HCM
News
- HUTCHMED (HCM) had its price target lowered by Bank of America Corporation from $21.00 to $20.00. They now have a "buy" rating on the stock.MarketBeat
- HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in ChinaGlobeNewswire
- Intended Retirement of Independent Non-executive Director and changes of composition of board committeesGlobeNewswire
- HUTCHMED H2 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- HUTCHMED Reports 2025 Full Year Results and Business UpdatesGlobeNewswire
HCM
Sec Filings
- 3/16/26 - Form 3
- 3/16/26 - Form 6-K
- 3/11/26 - Form 3
- HCM's page on the SEC website